Literature DB >> 19330460

3D-QSAR and molecular docking studies of 4-anilinoquinazoline derivatives: a rational approach to anticancer drug design.

Sisir Nandi1, Manish C Bagchi.   

Abstract

The present article is an attempt to formulate the three-dimensional quantitative structure-activity relationship (3D-QSAR) modeling of 4-anilinoquinazoline derivatives having promising anticancer activities inhibiting epidermal growth factor (EGFR) kinase. Molecular field analysis was applied for the generation of steric and electrostatic descriptors based on aligned structures. Partial least-squares (PLS) method was applied for QSAR model development considering training and test set approaches. The PLS models showed some interesting results in terms of internal and external predictability against EGFR kinase inhibition for such type of anilinoquinazoline derivatives. Steric and electrostatic field effects are discussed in the light of contribution plot generated. Finally, molecular docking analysis was carried out to better understand of the interactions between EGFR target and inhibitors in this series. Hydrophobic and hydrogen-bond interactions lead to identification of active binding sites of EGFR protein in the docked complex.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330460     DOI: 10.1007/s11030-009-9137-9

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  17 in total

1.  Usefulness of graphical invariants in quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type.

Authors:  Manish C Bagchi; Bhim C Maiti; Denise Mills; Subhash C Basak
Journal:  J Mol Model       Date:  2003-12-23       Impact factor: 1.810

2.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

Authors:  R D Cramer; D E Patterson; J D Bunce
Journal:  J Am Chem Soc       Date:  1988-08-01       Impact factor: 15.419

3.  Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming.

Authors:  D K Gehlhaar; G M Verkhivker; P A Rejto; C J Sherman; D B Fogel; L J Fogel; S T Freer
Journal:  Chem Biol       Date:  1995-05

4.  Quantitative structure-activity relationship (QSAR) studies of quinolone antibacterials against M. fortuitum and M. smegmatis using theoretical molecular descriptors.

Authors:  Manish C Bagchi; Denise Mills; Subhash C Basak
Journal:  J Mol Model       Date:  2006-08-24       Impact factor: 1.810

5.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

6.  5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.

Authors:  Peter Ballard; Robert H Bradbury; Laurent F A Hennequin; D Mark Hickinson; Paul D Johnson; Jason G Kettle; Teresa Klinowska; Remy Morgentin; Donald J Ogilvie; Annie Olivier
Journal:  Bioorg Med Chem Lett       Date:  2005-10-01       Impact factor: 2.823

Review 7.  The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases.

Authors:  W A Denny
Journal:  Farmaco       Date:  2001 Jan-Feb

8.  Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.

Authors:  Laurent F A Hennequin; Peter Ballard; F Tom Boyle; Bénédicte Delouvrié; Rebecca P A Ellston; Chris T Halsall; Craig S Harris; Kevin Hudson; Jane Kendrew; J Elizabeth Pease; Helen S Ross; Peter Smith; Jennifer L Vincent
Journal:  Bioorg Med Chem Lett       Date:  2006-03-03       Impact factor: 2.823

9.  Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.

Authors:  G W Rewcastle; W A Denny; A J Bridges; H Zhou; D R Cody; A McMichael; D W Fry
Journal:  J Med Chem       Date:  1995-09-01       Impact factor: 7.446

10.  Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor.

Authors:  Jennifer Stamos; Mark X Sliwkowski; Charles Eigenbrot
Journal:  J Biol Chem       Date:  2002-08-23       Impact factor: 5.157

View more
  7 in total

1.  Analysis of B-Raf[Formula: see text] inhibitors using 2D and 3D-QSAR, molecular docking and pharmacophore studies.

Authors:  Reza Aalizadeh; Eslam Pourbasheer; Mohammad Reza Ganjali
Journal:  Mol Divers       Date:  2015-08-15       Impact factor: 2.943

2.  3D-QSAR and molecular docking analysis of biphenyl amide derivatives as p38α mitogen-activated protein kinase inhibitors.

Authors:  Pravin Sundarao Ambure; Rahul Prakashchand Gangwal; Abhay T Sangamwar
Journal:  Mol Divers       Date:  2012-01-07       Impact factor: 2.943

Review 3.  Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors.

Authors:  Terry-Elinor Reid; Joseph M Fortunak; Anthony Wutoh; Xiang Simon Wang
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

4.  Identification of potent EGFR inhibitors from TCM Database@Taiwan.

Authors:  Shun-Chieh Yang; Su-Sen Chang; Hsin-Yi Chen; Calvin Yu-Chian Chen
Journal:  PLoS Comput Biol       Date:  2011-10-13       Impact factor: 4.475

5.  QSAR based model for discriminating EGFR inhibitors and non-inhibitors using Random forest.

Authors:  Harinder Singh; Sandeep Singh; Deepak Singla; Subhash M Agarwal; Gajendra P S Raghava
Journal:  Biol Direct       Date:  2015-03-25       Impact factor: 4.540

6.  Anti-infective potential of hydroalcoholic extract of Punica  granatum peel against gram-negative bacterial pathogens.

Authors:  Chinmayi Joshi; Pooja Patel; Vijay Kothari
Journal:  F1000Res       Date:  2019-01-18

7.  QSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFR.

Authors:  Jagat Singh Chauhan; Sandeep Kumar Dhanda; Deepak Singla; Subhash M Agarwal; Gajendra P S Raghava
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.